TMEM263

Across TCGA pan-cancer cohorts, TMEM263 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TMEM263’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TMEM263 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TMEM263 is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.

CCRCC, LUAD, and HNSC are the cancer types where TMEM263 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TMEM263 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	+0.708	<.001	12	view →
LUAD	Male	III,IV	+0.868	<.001	9	view →
HNSC	Male	IV	+0.367	<.001	9	view →
LSCC	Female	All	+0.326	<.001	8	view →
COAD	All	All	−0.093	.023	4	view →
OV	All	All	+0.506	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TMEM263–CCRCC

Open the CCRCC breakdown →